ATE290391T1 - Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen - Google Patents

Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen

Info

Publication number
ATE290391T1
ATE290391T1 AT99957817T AT99957817T ATE290391T1 AT E290391 T1 ATE290391 T1 AT E290391T1 AT 99957817 T AT99957817 T AT 99957817T AT 99957817 T AT99957817 T AT 99957817T AT E290391 T1 ATE290391 T1 AT E290391T1
Authority
AT
Austria
Prior art keywords
lactobacillus
oral administration
prevention
treatment
urogenital infections
Prior art date
Application number
AT99957817T
Other languages
English (en)
Inventor
Gregor Reid
Andrew W Bruce
Original Assignee
Urex Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urex Biotech Inc filed Critical Urex Biotech Inc
Application granted granted Critical
Publication of ATE290391T1 publication Critical patent/ATE290391T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99957817T 1998-12-11 1999-12-10 Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen ATE290391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11196598P 1998-12-11 1998-12-11
PCT/CA1999/001182 WO2000035465A2 (en) 1998-12-11 1999-12-10 Oral administration of lactobacillus for the treatment and prevention of urogenital infection

Publications (1)

Publication Number Publication Date
ATE290391T1 true ATE290391T1 (de) 2005-03-15

Family

ID=22341404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957817T ATE290391T1 (de) 1998-12-11 1999-12-10 Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen

Country Status (15)

Country Link
US (1) US6479051B1 (de)
EP (1) EP1137423B1 (de)
JP (1) JP2003522731A (de)
KR (1) KR20010101171A (de)
AT (1) ATE290391T1 (de)
AU (1) AU1543400A (de)
BR (1) BR9916062A (de)
CA (1) CA2354054C (de)
DE (1) DE69924141D1 (de)
ID (1) ID30071A (de)
IL (1) IL143632A0 (de)
NZ (1) NZ512275A (de)
PL (1) PL348973A1 (de)
TR (1) TR200101699T2 (de)
WO (1) WO2000035465A2 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
WO2002016554A1 (fr) * 2000-08-25 2002-02-28 Wakamoto Pharmaceutical Co.,Ltd. Produits probiotiques contenant une bacterie de l'acide lactique
SE521022C2 (sv) * 2001-09-20 2003-09-23 Ellen Ab Mjölksyraproducerande bakterier för användning som probiotiska organismer i vaginan hos människa
MXPA03002957A (es) 2000-10-06 2005-06-30 Nestle Sa Uso de bacteria probiotica de acido lactico para balancear el sistema inmune de la piel.
MXPA03005465A (es) * 2000-12-18 2004-10-14 Probiohealth Llc Compuestos probioticos derivados de la cepa ke01 de lactobacillus casei.
NZ527493A (en) * 2001-02-06 2005-06-24 Nestle Sa Endotoxin binding by lactobacillus and bifidobacteria having hydrophobic surface properties and use of the bacteria in treating endotoxin ( LPS ) mediated disorders
EE04580B1 (et) * 2001-06-29 2006-02-15 Tartu �likool Mikroorganismi tüvi Lactobacillus fermentum ME-3 kui antimikroobne ja antioksüdantne probiootikum
BR0211384B1 (pt) * 2001-07-23 2014-07-29 Iams Company Método e aparelho para produção de um produto alimentício para gatos e cães
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
CA2461708C (en) * 2001-09-28 2012-08-07 Nutraceutix, Inc. Delivery system for biological component
US7829079B2 (en) * 2002-03-28 2010-11-09 Christian Hansen A/S Lactobacillus iners for the enhancement of urogenital health
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
WO2004062597A2 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
GB0410785D0 (en) * 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
US20060062774A1 (en) * 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal urogenital flora
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
WO2006045474A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactic acid bacteria strains useful against gastrointestinal pathogens and compositions containing same
WO2006045347A1 (en) * 2004-10-22 2006-05-04 Medinova Ag Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens
WO2006113475A2 (en) * 2005-04-15 2006-10-26 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20070082035A1 (en) 2005-10-06 2007-04-12 New York Blood Center, Inc. Anti-infective hygiene products based on cellulose acetate phthalate
ES2388198T5 (es) * 2007-02-28 2020-07-14 Mjn Us Holdings Llc Lactobacillus Rhammosus GG inactivado para tratar la inflamación sistémica en bebés
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
US20110064706A1 (en) * 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
US20090226548A1 (en) * 2008-01-11 2009-09-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using a synergistic cranberry derivative and d-mannose composition
US20110256179A1 (en) * 2008-11-17 2011-10-20 Essum Ab Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains
EP2206506A1 (de) * 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotische Formulierungen
JP5645192B2 (ja) * 2009-07-16 2014-12-24 国立大学法人広島大学 口腔内疾患の予防、改善又は治療剤
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
AU2010339573B2 (en) * 2009-12-31 2014-08-28 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
NZ618935A (en) 2010-08-04 2014-03-28 Karma Medical Prod Co Ltd Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP2428214A1 (de) 2010-09-14 2012-03-14 HSO Health Care GmbH Zusammensetzungen für die vaginale und orale Verabreichung des Lactobacillus und Verwendungen davon
EE05750B1 (et) * 2011-02-25 2015-06-15 OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine
WO2012118535A1 (en) * 2011-03-01 2012-09-07 Quorum Innovations, Llc Materials and methods for treating conditions associated with pathogenic biofilm
ES2636439T3 (es) 2011-03-09 2017-10-05 Regents Of The University Of Minnesota Composiciones y métodos para el trasplante de microbiota de colon
US20120230957A1 (en) 2011-03-09 2012-09-13 Northwestern University Compositions and methods for treatment of pain
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
KR101287126B1 (ko) * 2011-10-28 2013-07-17 대상에프앤에프 주식회사 식물성유산균발효액을 함유하는 질염 및 요로감염 예방 및 치료용 약학 조성물
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
AU2013240289B2 (en) 2012-03-29 2018-01-25 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2013150497A1 (en) * 2012-04-05 2013-10-10 Compagnie Gervais Danone Lactobacillus rhamnosus food grade bacteria
FR2992973B1 (fr) 2012-07-09 2015-12-18 S P M D Nouvelle souche de lactobacillus crispatus
FR2992861B1 (fr) 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
US20150374764A1 (en) * 2013-02-07 2015-12-31 Organobalance Gmbh Composition comprising lactobacillus and a carrier
CA3101218A1 (en) 2013-03-14 2014-09-25 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ITMI20130793A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
EP3881680A1 (de) 2014-10-31 2021-09-22 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung von störungen
EP3064072A1 (de) * 2015-02-11 2016-09-07 AB-Biotics S.A. Probiotische Lactobacillus Stämme und ihre Verwendung zur Behandlung von Harnwegsinfektionen
CN107529789A (zh) 2015-04-28 2018-01-02 马斯公司 制备灭菌湿宠物食品的方法
WO2016181228A2 (en) 2015-05-11 2016-11-17 Mybiotix Pharma Ltd. Systems and methods for growing a biofilm of probiotic bacteria on solid particles for colonization of bacteria in the gut
DK3297644T3 (da) 2015-05-22 2022-04-11 Univ Arizona State Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer
CN108076643B (zh) * 2015-06-29 2021-09-21 辉凌制药公司 用于治疗例如细菌性***病的鼠李糖乳杆菌细菌
FR3048361B1 (fr) 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
KR102380134B1 (ko) 2016-05-25 2022-03-29 마이바이오틱스 파마 엘티디. 미생물총 치료를 위한 조성물 및 방법
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
JP7111699B2 (ja) * 2016-09-16 2022-08-02 デュポン ニュートリション バイオサイエンシーズ エーピーエス 細菌
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
WO2018218159A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
EP3664823B1 (de) 2017-08-07 2024-06-05 Finch Therapeutics Holdings LLC Zusammensetzung zur verwendung bei der vorbeugung oder behandlung von enterokokkalen bluteninfektion
EP3675882A4 (de) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit mikrobiomen
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
US20210268046A1 (en) * 2020-02-18 2021-09-02 HoneyHills TX, LLC Cannabinoid & probiotic suppositories & methods of use
WO2022043223A1 (en) 2020-08-28 2022-03-03 Chr. Hansen A/S Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate
CN112708583B (zh) * 2021-01-29 2022-05-17 重庆第二师范学院 一种发酵乳杆菌lf-schy34及其应用
KR102337951B1 (ko) * 2021-06-25 2021-12-13 주식회사 비피도 요로감염 개선, 예방 또는 치료를 위한 락토바실러스 헬베티쿠스 gut10 균주 및 이를 포함하는 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE469875C (sv) 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
US5733568A (en) * 1993-12-03 1998-03-31 Lafor Laboratories Limited Micro-encapsulated lactobacilli for medical applications
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6051552A (en) * 1996-05-30 2000-04-18 Urex Biotech, Inc. Lactobacillus therapies
ES2283027T3 (es) * 1996-11-29 2007-10-16 Bio K + International Inc. Fermento lactico que comprende una cepa particular de lactobacilus acidofilus y utilizacion del mismo.

Also Published As

Publication number Publication date
DE69924141D1 (de) 2005-04-14
EP1137423A2 (de) 2001-10-04
IL143632A0 (en) 2002-04-21
TR200101699T2 (tr) 2002-06-21
PL348973A1 (en) 2002-06-17
CA2354054C (en) 2011-04-12
BR9916062A (pt) 2002-09-24
US6479051B1 (en) 2002-11-12
AU1543400A (en) 2000-07-03
KR20010101171A (ko) 2001-11-14
JP2003522731A (ja) 2003-07-29
NZ512275A (en) 2003-11-28
ID30071A (id) 2001-11-01
CA2354054A1 (en) 2000-06-22
WO2000035465A3 (en) 2000-12-28
EP1137423B1 (de) 2005-03-09
WO2000035465A2 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
ATE407687T1 (de) Probiotisches milchsäurebakterium zur behandlung bakterieller infektionen in zusammenhang mit sids
ATE391509T1 (de) Von lactobacillus casei ke01 stamm abgeleitete probiotische verbindungen
HU9603251D0 (en) Lactobacillus strains of human origin, their compositions and uses thereof
DE69802260T2 (de) Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
WO2000071138A3 (en) Oral administration of lactobacillus for the maintenance of health in women
FI20001460A (fi) Probiootit atooppisten sairauksien primaariseen ehkäisyyn
ATE302265T1 (de) Einen lactobacillus-stamm enthaltende zusammensetzung und verwendungen davon
HK1094455A1 (en) Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
BR0008920A (pt) Cepas de lactobacillus capazes de prevenirdiarréia causada por bactéria patogênica erotaviroses
CA2314775A1 (en) Novel lactic acid bacterial preparation that reduces triglycerides and cholesterol
BR0012973B1 (pt) Uso de bactéria do ácido láctico pertencente ao gênero Bifidobacterium, e composição alimentícia ou farmacêutica.
ATE307575T1 (de) Zusammensetzung geeignet als nahrungsmittelzusatz und zur anwendung bei darmerkrankungen sowie bei veränderter darmflora
NO20014788D0 (no) En sammensetning for senkning av konsentrasjonen av sykdomsfremkallende tarmpeptider
DE69739592D1 (de) Erkennung, vorbeugung und behandlung papillomatöser digitaler dermatitis
DE60012521D1 (de) BAKTERIENSTAMM LACTOBACILLUS ACIDOPHILUS N.V. EP 317/402 NARINE, WELCHER ZUR HERSTELLUNG VON ZUSAMMENSETZUNGEN UND VON DIäTETISCHEN, THERAPEUTISCHEN UND PROPHYLAKTISCHEN PRODUKTEN ZUR BEHANDLUNG VON DYSBAKTERIOSE UND DEREN FOLGEN VERWENDET WIRD
MD1305B2 (en) Nutrient medium for selective separation of the Enterobacteriaceae family representatives
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
MX9708385A (es) Derivados novedosos de tetraciclina, composiciones que los contienen, y el uso de las mismas.
MD20010055A (ro) Preparat microbian sanogenic pentru profilaxia şi tratamentul disbacteriozei intestinale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties